Company
Argent BioPharma Ltd
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 1 of 2
MGC Pharma continues focus on sales growth with reopening of upgraded factory
The planned shutdown of its Slovenian plant and seasonal trends were responsible for the fall in revenue to US$765k in the September quarter
MGC Pharmaceuticals delivers positive Long-COVID clinical study results
“That the product could help to explain changes in the symptoms of Long-COVID patients is an extremely promising development for the company, with significant potential commercial developments we hope to explore further through future studi
MGC Pharma achieves a series of major operational and quality milestones
"It is important the business is well positioned to service demand, both in terms of our production capacity, and the progress of our products through the clinical pipeline," said the company's managing director Roby Zomer
MGC Pharmaceuticals hits key European and US milestones
MGC has also fast-tracked production to deliver 50,000 units of ArtemiC™ Rescue to AMC Holdings in a single shipment.
MGC Pharmaceuticals appoints Hannam & Partners as UK capital markets advisor; transitions board
The company has tapped Hannam & Partners as financial and corporate advisors in an effort to maximise enterprise value. At the same time, the company has appointed a new chief operating officer and transitioned chair Brett Mitchell into a n
MGC Pharmaceuticals Ltd appoints new COO and UK advisor
Yifat Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline
MGC Pharma shares jump 8% after it reveals encouraging early data from dosing study
None of the 16 patients administered CimetrA demonstrated significant complications related to the illness
MGC Pharmaceuticals delivers encouraging results from CimetrA dose-finding study against COVID-related infections
Preclinical and clinical results to date have demonstrated CimetrA™'s mechanism of action as an anti-inflammatory and immunomodulatory agent which is effective in the prevention of an infection of the different variants of SARS-CoV-2.
MGC Pharma sees sales jump 57%
The company specialises in developing plant-based and cannabis-derived treatments for ailments as diverse as inflammatory diseases, Covid and cancer
MGC Pharmaceuticals makes final project payment for phytomedicine manufacturing hub
MGC Pharma is targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.
MGC Pharmaceuticals secures additional ~US$1 million order for anti-inflammatory product
3,500 units of ArtemiC Rescue already delivered to AMC, resulting in the new purchase order to be delivered into the US over the next 3 months.
MGC Pharmaceuticals fields positive data from study on drug-resistant epilepsy medication
The clinical study included the use of a driving simulator, which assesses whether a drug may cause somnolence or impair cognition, and its results will be used to support safety data from future trials for submission to regulatory agencies
MGC Pharmaceuticals receives first tranche of its US$10 million facility with Mercer Street Capital Partners
The new facility provides MGC Pharma with access to significant capital to fund the execution of its business commercialisation strategy, primarily with Sciensus Rare in the UK and EU and AMC in the USA.
MGC Pharmaceuticals inks US$10 million financing agreement with US-based Mercer Street Capital
This financing facility provides the company with access to significant capital in order to execute its business commercialisation strategy.
MGC Pharmaceuticals acquires 40% stake in ZAM Software Ltd to accelerate rollout of ZAM app
The company believes the integration of this learning AI algorithm could be revolutionary in the health sector, positioning the ZAM app far ahead of market peers.
MGC Pharmaceuticals ‘confident’ as products continue progress through regulatory approval process
Getting pharmaceutical products through the regulatory approval process takes time, particularly when the products are phytocannabinoids"
MGC Pharmaceuticals appoints experienced industry executive in new chief commercial officer role
Robert Clements, an expert in market development for rare and chronic diseases, has been appointed to the new role to help drive forward the company’s strategy and goal of becoming a leading supplier of plant-derived medicines.
MGC Pharmaceuticals shares jump 28% after long Covid success
The data read-out showed ArtemiC Support had a statistically significant impact on shortness of breath, cough, lack of energy, headache and mental confusion
MGC Pharmaceuticals secures South African ethics approval for CimetrA™ dose-finding study in patients with COVID-19
Results have so far indicated CimetrA could be used to treat a wide spectrum of inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), influenza, and dermatological diseases, among others.
MGC Pharma launches data collecting 'online doctor' app with machine learning algorithm
The app will “will serve as an 'online doctor', both collecting data and learning from it to predict conflicts in treatments, increasing efficiency for medical practitioners”, said MGC co-founder Roby Zomer
MGC Pharma hails the potential of lead asset
Researchers found CimetrA effectively blocked a key mechanism in inflammatory diseases such as arthritis and asthma
MGC Pharmaceuticals shares rise after preliminary results indicate wide-ranging application of CimetrA as an anti-inflammatory treatment
Results indicate that CimetrA may have a wider-ranging application beyond the treatment of the symptoms of COVID-19, which has been the primary focus of clinical trials to date.
MGC Pharmaceuticals finalises plans for US clinical trial of CimetrA
"We are excited to start the trials in collaboration with USF at the earliest opportunity this year, particularly with COVID-19 spikes and new variants emerging every few months," said CEO Roby Zomer
MGC Pharma's early-stage glioblastoma delivers 'outstanding results'
The three year-study will be followed by additional research
MGC Pharma says trial shows key treatment can benefit dementia patients
“This important finding indicates not only improvement in the health status of the patients, but also the improved quality of life of the families and caregivers that are taking care of dementia patients,” MGC said
MGC Pharmaceuticals' ArtemiC oral spray 'bears great promise for COVID-19 patients', says peer-reviewed scientific paper
The article assessing the output from a study of 50 people with the virus was carried in the Journal of Cellular and Molecular Medicine
MGC Pharma delivery technology for epilepsy drug receives patent protection
“We are very pleased that the patent for our proprietary drug delivery system has now been granted by the Slovenian Intellectual Property Office,” said MGC’s managing director and co-founder, Roby Zomer
MGC Pharmaceuticals enters Indian market through tie-up with HempStreet
HempStreet will distribute CimetrA and CannEpil, MGC’s cannabis-based formulations for treating Covid-19, in India
MGC Phamaceuticals reports good sales in Australia in latest quarter
Post the period, MGC pharma signed a new distribution agreement with Netherlands-based Sciensus Rare
MGC Pharmaceuticals patent for CimetrA cannabinoid compound approved
The product has potential efficacy in relation to the regulation of the human body's circadian rhythm and homeostasis, which promotes an immune response to bacterial, viral, fungal and parasitic infections.
MGC Pharma hails patent grant for inflammatory treatment
Its lead asset CimetrA is a plant-based drug containing curcumin and Boswellia and has been developed to treat acute and chronic inflammation caused by flu and viral diseases such as Covid